Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

20093,610 citationsJournal Articlebronze Open Access

Authors

Peter C.C. Fong · Institute of Cancer Research

David S. Boss · The Netherlands Cancer Institute

Timothy A. Yap · Institute of Cancer Research

Andrew Tutt · King's College London

Peijun Wu · Breakthrough

Marja Mergui‐Roelvink · The Netherlands Cancer Institute

Peter G. Mortimer

Abstract

Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NCT00516373.)

Topics & Keywords

PARP inhibition in cancer therapy BRCA gene mutations in cancer DNA Repair Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 361, Issue 2, pp. 123-134

DOI: 10.1056/nejmoa0900212

Field-Weighted Citation Impact: 150.02